049 transporter activity Group GOID Gene symbol or representative public ID Signal GO:0005030 NTRK1, NTRK2
transduction GO:0001614 P2RX4, P2RY2, ENSGALG00000012080 GO:0016502 P2RX4, P2RY2, ENSGALG00000012080 GO:0043121 NTRK1, NTRK2
GO:0035586 P2RX4, P2RY2, ENSGALG00000012080 GO:0004888 OXTR, LOC431251, SSTR3, CHRM2, ADRA2B, P2RX4, P2RY2, EDNRB2, GABRB2, GABRG2, LOC428961, NPFFR2, GRIN2B, GRIN3A, NTRK1, NTRK2
, EPHB6, DDR2, TMPRSS6, PCSK5, CCKAR, IFNAR2, CSF1R, TLR5, OR10A7, LOC768958, LOC769317, LOC777484, GPR39, GPR97, ENSGALG00000017405, ENSGALG00000017093, ENSGALG00000012080.
These targets included genes for multiple neurotransmitter receptors (GRIA3, GRM3, and GABRR2), PCLO [piccolo (presynaptic cytomatrix protein)], and NTRK2
(neurotrophic tyrosine kinase, receptor, type 2).
Immunohistochemical expression of NTRK1 and NTRK2 has been reported as strong in tissues exhibiting squamous differentiation but is less consistent or absent in glandular tissues, (11) suggesting that these markers may be effective discriminators between squamous and glandular subtypes of non-small cell lung carcinoma.
2508) and monoclonal rabbit anti-human NTRK2 (clone 80G2, catalog no.
What constitutes positive NTRK1 and NTRK2 immunohistochemical staining is not well defined.
To be included in the statistical analysis, each lung cancer case required at least 30 days of follow-up information and interpretable scores for both NTRK1 and NTRK2 immunostaining.
NTRK1 and NTRK2 Expression in Normal and Non-Lung Tumor Tissue
Prior to immunostaining the lung cancer TMAs, NTRK1 and NTRK2 immunostaining was assessed on control tissues.
The results of immunohistochemical staining for NTRK1 and NTRK2 by lung cancer subtype are summarized in Table 3.